Abstract
PTEN is a tumor suppressor gene localized to human chromosome 10q23.31, a genomic region frequently lost in glioblastoma and prostate cancer. The fact that PTEN encodes a lipid phosphatase with specificity towards phosphatidylinositol-3,4,5-triphosphate renders it a gate-keeper of the phosphatidylinositol 3-kinase pathway. Numerous physiological processes have been ascribed to this evolutionarily conserved molecule including proliferation, cell size determination, survival, differentiation, and cell fate specification. Indeed, mutation in PTEN gene is the genetic cause of Cowden Syndrome. Structurally, the 54-kilodalton protein is composed of two major functional domains crucial for catalytic and membrane binding functions. Additional regulatory regions in both amino- and carboxyl-termini further dictate its structural integrity, catalytic activity, and subcellular localization. Extensive characterization of PTEN primary coding sequence has revealed a multitude of post-translational modifications that fine-tune its biochemical properties. These include phosphorylation, ubiquitination, redox modifications, and acetylation. This article aims to provide an indepth review of the diverse post-translational modifications of PTEN, focusing on their biological relevance in both normal and cancer cells. The potential applications to cancer therapy by modulating the post-translational modifications of PTEN will also be discussed.
Keywords: PTEN, phosphatase, tumor suppressor, post-translational, phosphorylation, ubiquitination, redox, acetylation, Acute Myeloid Leukemia, Epidermal Growth Factor Receptor, Glutathione-S-Transferase, Histone acetyltransferase, Promyelocytic Leukemia Protein, Reactive Oxygen Species, Histone deacetylase
Current Cancer Drug Targets
Title: Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Volume: 11 Issue: 5
Author(s): G. Singh and A. M. Chan
Affiliation:
Keywords: PTEN, phosphatase, tumor suppressor, post-translational, phosphorylation, ubiquitination, redox, acetylation, Acute Myeloid Leukemia, Epidermal Growth Factor Receptor, Glutathione-S-Transferase, Histone acetyltransferase, Promyelocytic Leukemia Protein, Reactive Oxygen Species, Histone deacetylase
Abstract: PTEN is a tumor suppressor gene localized to human chromosome 10q23.31, a genomic region frequently lost in glioblastoma and prostate cancer. The fact that PTEN encodes a lipid phosphatase with specificity towards phosphatidylinositol-3,4,5-triphosphate renders it a gate-keeper of the phosphatidylinositol 3-kinase pathway. Numerous physiological processes have been ascribed to this evolutionarily conserved molecule including proliferation, cell size determination, survival, differentiation, and cell fate specification. Indeed, mutation in PTEN gene is the genetic cause of Cowden Syndrome. Structurally, the 54-kilodalton protein is composed of two major functional domains crucial for catalytic and membrane binding functions. Additional regulatory regions in both amino- and carboxyl-termini further dictate its structural integrity, catalytic activity, and subcellular localization. Extensive characterization of PTEN primary coding sequence has revealed a multitude of post-translational modifications that fine-tune its biochemical properties. These include phosphorylation, ubiquitination, redox modifications, and acetylation. This article aims to provide an indepth review of the diverse post-translational modifications of PTEN, focusing on their biological relevance in both normal and cancer cells. The potential applications to cancer therapy by modulating the post-translational modifications of PTEN will also be discussed.
Export Options
About this article
Cite this article as:
Singh G. and M. Chan A., Post-Translational Modifications of PTEN and their Potential Therapeutic Implications, Current Cancer Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/156800911795655930
DOI https://dx.doi.org/10.2174/156800911795655930 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gold Nanoparticles: Promising Agent to Improve the Diagnosis and Therapy of Cancer
Current Drug Metabolism Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!
Current Pharmaceutical Biotechnology Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Analysis of Differential Gene Expression Based on Bayesian Estimation of Variance
Current Bioinformatics Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications
Current Cancer Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Iron Oxide Nanoparticles Synthesized Via Green Tea Extract for Doxorubicin Delivery
Current Nanoscience Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine KiSS1-Induced GPR54 Signaling Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition via Protein Kinase D1
Current Molecular Medicine Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry